EP0188501A1 - Procede de preparation d'une composition pharmaceutique exer ant une influence sur le metabolisme des tissus ainsi qu'une action regeneratrice - Google Patents

Procede de preparation d'une composition pharmaceutique exer ant une influence sur le metabolisme des tissus ainsi qu'une action regeneratrice

Info

Publication number
EP0188501A1
EP0188501A1 EP85903353A EP85903353A EP0188501A1 EP 0188501 A1 EP0188501 A1 EP 0188501A1 EP 85903353 A EP85903353 A EP 85903353A EP 85903353 A EP85903353 A EP 85903353A EP 0188501 A1 EP0188501 A1 EP 0188501A1
Authority
EP
European Patent Office
Prior art keywords
milk
solution
crystal water
aluminium sulphate
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP85903353A
Other languages
German (de)
English (en)
Inventor
Szigfrid Szabo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Economix Kozgazdasz Egyetemi Kisszovetkezet
Original Assignee
Economix Kozgazdasz Egyetemi Kisszovetkezet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Economix Kozgazdasz Egyetemi Kisszovetkezet filed Critical Economix Kozgazdasz Egyetemi Kisszovetkezet
Publication of EP0188501A1 publication Critical patent/EP0188501A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/986—Milk; Derivatives thereof, e.g. butter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the invention relates to a process for the prepara ⁇ tion of a pharmaceutical composition influencing the tissue metabolism and having a regenerating action, the effect of which mainly appears in promoting the tissue regeneration and assuring the tissue metabolism; however, this composition is also useful, inter alia for abolish ⁇ ing spastic muscle states and for relieving pain.
  • the invention relates to the preparation of a pharmaceutical composition influencing the tissue metabolism and having a regenerating action.
  • the process of invention comprises adding crystal water- -free potassium aluminium sulphate to a milk kept a temperature abov 90 C, separating the solution from the solid material after the segregation of the dispersion thus obtained and optionally adding aromatizing, preserving and colouring agents to the solution.
  • the active agent of the composition prepared by using the process of invention is the whey obtained in the way described above. Although no mode of action is postulated, it is supposed that for the
  • the products the appropriate concentration of which is indispensable for the tissue regeneration in a given period, are provided by the amino acid content of the whey. It has been proved by investigating the acid-base balance and the gas tension parameters as well as the changes in the whole resting respiratory function of the human body that the composition is rapidly and significant ⁇ ly absorbed through the skin. The acid-base balance is shifted to a moderately metabolic acidosis which is then later shifted back to a mild alkalcsis as a consequence of the amino acid metabolism.
  • the function of the respiratory system also becomes more economical and the capacity thereof is enhanced by the composition of the invention.
  • composition of the invention metabolizing acidic substances, which are indispensable for a tissue regeneration, can be advantageously introduced into the organism through the skin, that is, in a fully new way.
  • acidic substances exert an advantageous influence on the interior homeostasis of the cells and of the intercellular substance through the acid-base balance.
  • the substances required fcr the tissue regeneration are directly provided to the cells by the amino acid content of the composition of invention through a direct diffusion, i.e. without the intervention of the systemic blood circulation.
  • a comparison to known oral or parenteral compositions is void of any sense.
  • fatty cow milk can preferably be used, however a less fatty cow milk or e.g. goat's milk can also be used.
  • crystal water-free potassium aluminium sulphate suitably alum heated at a temperature between 300 °C and 400 °C is used.
  • 1.6 to 2.1 g, depending from the" fat content of the milk, of crystal water-free potassium aluminium sulphate are suitably added portionwise to 1 litre of milk, preferably at. the boiling point of the milk, whereby the casein and fatty materials are precipitated. After some time, the supernatant becomes substantially pure and can be separated. For this purpose filtration and/or centrifu-gation are suitably used.
  • the thus-obtained solution is actually suitable for a therapeutical use, but an aromatizing agent should be added for masking the inconvenient odour of the materials arising from the milk and a preserving agent has to be mixed in for preventing the decomposition of the materials arising from the milk.
  • a colouring agent may also be added optionally to the composition for promoting the acceptability of the use thereof.
  • an extract arising from a medicinal plant /herb/ is used as an aromatizing agent, whereby the in- convenient odours are fully masked and simultaneously, the medicinal plant extract may have an own advantageous action.
  • the aqueous extract can be prepared in a manner known in the art, suitably by boiling a mixture containing an 1:1 ratio by weight of the medicinal plants with water for 5 minutes and queezing the juice obtained through a press.
  • any other aromatizing agent commonly used in- the pharmaceutical industry such as pine, hay or orange aroma, may be -used as aromatizing agent.
  • preservatives commonly used for prepar ⁇ ing pharmaceutical compositions may be used as preserving agents in the process of the invention
  • ft is suitable to use eth.ar.ol, preferably pure ethanol of 96 %.
  • eth.ar.ol preferably pure ethanol of 96 %.
  • a large-scale production e.g. 70 % by volume of whey, 23 % by volume of pure 96 % ethanol and 7 % by volume of a medicinal plant extract /optionally containing 96 % ethanol, suitably 1 litre of pure 96 % ethanol for each 4 litres of the aqueous .extract/, calculated for 1 litre of the pharmaceutical composition, may be used.
  • preservatives may also be employed, by the use of which the whey liable to fermentation is preserved, the amino acid contents are not damaged, the treated skin is not irritated and the preservating effect is exerted even if the composition of the invention comes into contact with the skin.
  • compositions prepared by using the process of the invention are utilized for pharmaceutical purposes as follows.
  • Suitable ready-for-use formulations of the composi ⁇ tions of the invention are the liniment, lotion and spray which may be prepared in a manner well-known in the pharmaceutical industry, optionally by employing the additives commonly used for these types of pharmaceutical formulations.
  • the amount and manner of the active substances used for a therapeutic purpose are dependent on a number of factors such as the status of the patient, the effectivity and concentration of the active substance as well as the formulation.
  • composition of the invention is suitably applied by infriction to the body part to be treated daily 2 to 5 times.
  • the treatment is carried out as follows.
  • composition of the invention is applied to the surface to be treated b " hand or in a spray form. After absorption, the treatment is repeated and, after the second absorption, a third infriction is made. It is essential to keep the surface to be treated wet for about 10 minutes. As mentioned above, this treatment can be accomplished daily 3 times.
  • compositions prepared according to the process of the invention are as follows.
  • a therapeutic chain reaction in several directions is started in the organism as a consequence of the regenerated advantageous cellular activity, whereby a rapid improvement or recovery is achieved in the following cases: a/ A regenerating action on the skin, muscle and bones: the restoration of ulcers, gangrenes and other wounds, as well as a rapid rehabilitation after muscle lesions, cartilage- and syndesmoplastic operations and the like; b/ Abolishment of metabolic disturbances: a restoring effect in vascular stenoses is achieved by the improvement of the metabolic economy in the musculature of the extremities, i.e.
  • composition of the invention shows an out ⁇ standing analgesic effect: the pain is abolished or ' alleviated to a minimum at 10 to 15 minutes after the infriction.
  • Fatty milk is heated to the boiling point and 1.8 g of the above-described spongy alum, calculated for 1 litre of milk, are added under continuous boiling. The mixture is then boiled for 10 minutes and after the complete precipitation of casein, the supernatant solid materials are removed from the milk surface by using a filter bag to give an opalescent, transparent liquid. After cooling down of the filtrate to a temperature between 35 °C and 40 °C, 1 litre of 96 % ethanol, calculated for each 4 litres of the filtrate, is added.
  • a decoction is prepared from 250 g of woundwort, 250 g of Glechoma hederacea L. and 250 g of herb-ovy with- 6 litres of water during 5 minutes, whereupon the juice of the medicinal plants are queezed through a press to give a decoction of about 4 litres. Each 4 litres of this decoction is mixed with 1 litre of 96% ethanol ' .
  • Example 1 The process described in Example 1 is followed, except that 200 g of woundwort, 200 g of Glechoma hederacea L. 200 g of herb-ovy and 200 g of silver-weed are used as medicinal plants.
  • Example 1 The action of the composition prepared as described in Example 1 was investigated on 60 patients suffering from vascular stenosis /arteriosclerosis obliterans or endarteriiti obliterans/. Simultaneously, a control group consisting of 25 patients was treated by a traditional method commonly used in the medicinal practice and a control group consist ⁇ ing of 25 patients was treated with a liquid having the same colour and odour as that of the agent but containing no whey /negative control/. The agent was applied daily 3 times to the affected body parts by infriction as described above.
  • the skin temperature was decreased by 3 to 4 °C, then it warmed back gradually and reached the original value as measurable on healthy individuals within 50 to 60 minutes. It was observed on using the composition of Example 1 for the treatment of vascular stenoses that the temperature of the sick side was lower than that of the healthy one. The above temperature decrease was observed also here, but it is considered to be very significant that the temperature of the sick extremity did not increase only to the starting value, but to a temperature identical with that of the healthy side, i.e. to a temperature higher than the starting value. When the agent was chronically applied, the resting skin temperature of the sick extremity was increased by 2 C on using infrictions daily 5 times for 2 weeks.
  • the composition prepared according to Example 1 was used on 17 patients within the course of rehabilitation following a plaster-bandage used 6 weeks after knee operations /cartilage and syndesmoplasty/.
  • a compress was used as described above. It was- stated that the severe pain appearing at the initial movements was significantly or nearly completely alleviated and the enhanced muscular tonus was also abolished. Thus, the restoration of the passive motion limits of the articulation was enhanced within a very short period and the tiredness, known as muscular strain, did not appear in the extremity during the active curative gymnastics. As a consequence, the rehabi ⁇ litation period was shortened by 20 to 50 % and the troubles connected with the movements of the patients " were significantly reduced.
  • Example 1 The action of the composition prepared as described in Example 1 was studied on 14 patients /as compared ' to 8 control patients/ on such types of neuritic diseases, where the irritation of a nerve was caused by a change of the condition of the musculature /functional neuritis/. In these cases, a trophic trouble was observed on the supplied area and a local blood circulation trouble was also found. The extent of the condition change was judged from the temperature of the sick area: the cooler was this area, the more pronounced was considered the change. The agent was applied to the affected area daily 5 times by infriction for 2 weeks. After ending the treatment, the collateral difference of 3 to 4 C disappeared.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Ce procédé consiste à ajouter un sulfate anhydre cristallin d'aluminium de potassium à un lait maintenu à une température dépassant 90oC, à séparer ensuite le matériau solide de la solution après la ségrégation de la dispersion obtenue et à ajouter éventuellement à la solution un agent aromatique, conservant ou colorant. La composition ci-décrite exerce une excellente action régénératrice sur la peau, les muscles et les os. Les troubles métaboliques des tissus sont également éliminés, ce qui permet d'obtenir une amélioration, par exemple, des sténoses vasculaires.
EP85903353A 1984-07-13 1985-07-12 Procede de preparation d'une composition pharmaceutique exer ant une influence sur le metabolisme des tissus ainsi qu'une action regeneratrice Withdrawn EP0188501A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU275184 1984-07-13
HU275184 1984-07-13

Publications (1)

Publication Number Publication Date
EP0188501A1 true EP0188501A1 (fr) 1986-07-30

Family

ID=10960944

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85903353A Withdrawn EP0188501A1 (fr) 1984-07-13 1985-07-12 Procede de preparation d'une composition pharmaceutique exer ant une influence sur le metabolisme des tissus ainsi qu'une action regeneratrice

Country Status (3)

Country Link
EP (1) EP0188501A1 (fr)
AU (1) AU4549985A (fr)
WO (1) WO1986000525A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3840946A1 (de) * 1987-02-09 1990-06-07 Hanko Laszlo Verwendung von aluminiumkaliumsulfat und/oder von 1 oder mehreren seiner hydrate

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU617661B2 (en) * 1987-02-24 1991-12-05 Thermalife International Pharmaceuticals Limited A method for manufacturing cosmetical, health and body care products
EP0408649A4 (en) * 1988-04-08 1991-11-27 Genetics Institute, Inc. Bone and cartilage inductive compositions
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB190806247A (en) * 1908-03-20 1908-09-03 Carl Albrecht Baechler Improvements in the Manufacture of Casein
AT41810B (de) * 1908-07-27 1910-04-11 Casein And Milk Ind Ltd Verfahren zur Abscheidung von Kaseïn unmittelbar aus der Milch.
US2721861A (en) * 1951-10-01 1955-10-25 Laurene O Paterson Process of preparing an aluminum caseinate
DE959219C (de) * 1954-07-03 1957-02-28 Merz & Co Verfahren zur Herstellung von Schleimsalben
CH635512A5 (de) * 1978-09-15 1983-04-15 Verband Aargauischer Kaeserei Schaumbad-praeparat.
FR2446634A1 (fr) * 1979-01-16 1980-08-14 Nestle Sa Soc Ass Tech Prod Composition a base d'hydrolysat de lactalbumine pour le traitement et les soins de la peau
FR2460135A1 (fr) * 1979-07-02 1981-01-23 Liotet Serge Composition a usage externe a base de colostrum
AT363193B (de) * 1979-08-24 1981-07-10 Eberle M & Co Doris Cosmetic Verfahren zur herstellung eines kosmetischen praeparates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8600525A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3840946A1 (de) * 1987-02-09 1990-06-07 Hanko Laszlo Verwendung von aluminiumkaliumsulfat und/oder von 1 oder mehreren seiner hydrate

Also Published As

Publication number Publication date
WO1986000525A1 (fr) 1986-01-30
AU4549985A (en) 1986-02-10

Similar Documents

Publication Publication Date Title
EP1304115B1 (fr) Compositions antipruritiques et compositions favorisant la cicatrisation des blessures
DE3032481C2 (fr)
US5427776A (en) Aloe water preparation
EP0308210A1 (fr) Traitement topique des troubles de la peau malade
WO2006032091A2 (fr) Composition a base d'herbes medicinales
IL185775A (en) Products derived from grenade and used for the treatment of wounds and skin lesions
JPH0565489B2 (fr)
EP0188501A1 (fr) Procede de preparation d'une composition pharmaceutique exer ant une influence sur le metabolisme des tissus ainsi qu'une action regeneratrice
CA2283314C (fr) Pommade destinee au traitement de brulures et d'autres maladies cutanees
Fyfe Pocket Essentials of Modern Materia Medica and Therapeutics
EP0329834A2 (fr) Composition pour la régénération et repousse des cheveux, curative et germicide pour la peau et les muqueuses
US5972340A (en) Slimming cream based on plants
JPH0532555A (ja) ステビア系内服液及びその製造方法
JPS5913716A (ja) 外用組成物
JP2813624B2 (ja) 循環不全治療用医薬組成物
JPH0310609B2 (fr)
JPS62111908A (ja) 皮膚外用剤
RU2124363C1 (ru) Способ лечения дерматологических заболеваний
Waring Remarks on the uses of some of the bazaar medicines and common medical plants of India
King et al. The eclectic dispensatory of the United States of America
CN1066043C (zh) 一种治疗骨质增生和腰椎间盘突出的中药
KR20040035950A (ko) 자연식물 추출성분으로 이루어진 기능성 입욕제 조성물 및그 제조방법
JP2757188B2 (ja) かゆみ止め剤
Fyfe The Essentials of modern materia medica and therapeutics
CN114225003A (zh) 补火助阳、温中散寒的中药组合物及其制备方法和应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19860617

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SZABO, SZIGFRID